Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 Genitourinary Cancers Symposium /
Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma

26th - 28th Feb 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.02.15
Views: 2970
Rating:

Dr Mark Beresford - Royal United Hospitals Bath, Bath, UK

Dr Mark Beresford talks to ecancertv at ASCO GU 2015 reflecting on the initial results of the ASSURE trial where adjuvant treatment with sorafenib or sunitinib is used for localised renal carcinoma. Neither sorafenib nor sunitinib provide improved outcomes. Other trials such as SORCE which looks at sorafenib and ATLAS which looks at axitinib question the duration of treatment.

Read the news story on the ASSURE trial here.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation